Adnagen GmbH
Records under this name other than the patents Adnagen GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Showing 1 to 5 of 5 · Back to Adnagen GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,858,757 | Monoclonal antibodies with specificity for fetal erythroid cells Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,536,312 | Monoclonal antibodies with specificity for fetal erythroid cells Formerly held Term ended Term ended Aug 17, 2025 · From the USPTO record | Term ended | Term ended Aug 17, 2025 | From the USPTO record |
| US 9,194,871 | Monoclonal antibodies with specificity for fetal erythroid cells Term ended Ended no later than Mar 31, 2025 · From the USPTO record | Term ended | Ended no later than Mar 31, 2025 | From the USPTO record |
| US 9,453,841 | Monoclonal antibodies with specificity for fetal erythroid cells Formerly held Term ended Ended no later than Mar 31, 2025 · From the USPTO record | Term ended | Ended no later than Mar 31, 2025 | From the USPTO record |
| US 7,507,528 | Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells Term ended Ended no later than May 17, 2022 · From the USPTO record | Term ended | Ended no later than May 17, 2022 | From the USPTO record |